The ability to accurately predict survival/life expectancy in ATTR-CM can better inform clinical decision-making. In incurable illnesses of which prognosis is poor, the ability to provide patients ...

Air provided by high flow nasal therapy may more closely match the humidity and temperatures in the lower respiratory tract. Long-term high-flow nasal therapy reduces the subjective assessment of ...

Unlike the pivotal studies of ruxolitinib or fedratinib, phase 3 trials for pacritinib (PAC) enrolled patients with INT-1 risk. During the studies, a spleen volume reduction of at least 35% (SVR35) ...